Find clinical trials for Merck. Search for Merck clinical trials in different cities and states across the United States.
Filter
Filter results
Results: 116
Active & Responsive
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
for
Triple Negative Breast Neoplasms
Location: Quebec, Chicoutimi, Mineola NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06841354
Phase3, Recruiting
Active & Responsive
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
for
Hypertension, Pulmonary
Location: Durham NC
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06814145
Phase2, Recruiting
Active & Responsive
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
for
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Location: Hillsborough NJ, Montreal, Philadelphia PA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07266831
Phase2, Phase3, Recruiting
Active & Responsive
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
for
Healthy, Hepatic Impairment
Location: Orlando FL, San Antonio TX, Chandler AZ
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18 - 70+
Code: NCT07219550
Phase1, Recruiting
Active & Responsive
A Study of V118E in Healthy Participants (V118E-003)
for
Healthy
Location: Hallandale FL, South Miami FL, Springfield MO,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18 - 49
Code: NCT07168915
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
for
Human Immunodeficiency Virus (HIV),
Location: The Bronx NY, Newark NJ, Philadelphia PA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 16+
Code: NCT07044297
Phase3, Recruiting
Active & Responsive
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
for
Healthy
Location: Columbus OH, Springfield MO, Kansas City MO, Lincoln NE,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 12 - 30
Code: NCT06655324
Phase1, Recruiting
Active & Responsive
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
for
Coronavirus Disease (COVID-19)
Location: The Bronx NY, New York NY, Teaneck NJ, Newark NJ,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06667700
Phase3, Recruiting
Active & ResponsiveNew
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
for
Non-small Cell Lung Cancer
Location: Montreal, Kingston, Grand Forks ND, Lincoln NE, Reno NV
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07513376
Phase3, Recruiting
Active & Responsive
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
for
Generalized Myasthenia Gravis
Location: Farmington CT, Burlington VT, Washington D.C. DC,
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany